{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:17:18Z","timestamp":1783462638311,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T00:00:00Z","timestamp":1452902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00520-015-3057-2","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T00:17:29Z","timestamp":1452903449000},"page":"2677-2684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor"],"prefix":"10.1007","volume":"24","author":[{"given":"Ruth","family":"Pettengell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,16]]},"reference":[{"key":"3057_CR1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228\u2013237. doi: 10.1002\/cncr.11882","journal-title":"Cancer"},{"key":"3057_CR2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328\u2013340","journal-title":"Ann Intern Med"},{"key":"3057_CR3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","volume":"318","author":"JL Gabrilove","year":"1988","unstructured":"Gabrilove JL, Jakubowski A, Scher H, et al. (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414\u20131422. doi: 10.1056\/NEJM198806023182202","journal-title":"N Engl J Med"},{"key":"3057_CR4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.1989.7.10.1554","volume":"7","author":"G Morstyn","year":"1989","unstructured":"Morstyn G, Campbell L, Lieschke G, et al. (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554\u20131562","journal-title":"J Clin Oncol"},{"key":"3057_CR5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","volume":"325","author":"J Crawford","year":"1991","unstructured":"Crawford J, Ozer H, Stoller R, et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164\u2013170. doi: 10.1056\/NEJM199107183250305","journal-title":"N Engl J Med"},{"key":"3057_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","volume":"29A","author":"V Trillet-Lenoir","year":"1993","unstructured":"Trillet-Lenoir V, Green J, Manegold C, et al. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319\u2013324","journal-title":"Eur J Cancer"},{"key":"3057_CR7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/JTO.0b013e3181a52964","volume":"4","author":"U Gatzemeier","year":"2009","unstructured":"Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, del Giglio A (2009) XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 4:736\u2013740. doi: 10.1097\/JTO.0b013e3181a52964","journal-title":"J Thorac Oncol"},{"key":"3057_CR8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/10428190902756081","volume":"50","author":"A Engert","year":"2009","unstructured":"Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 50:374\u2013379. doi: 10.1080\/10428190902756081","journal-title":"Leuk Lymphoma"},{"key":"3057_CR9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","volume":"8","author":"A Giglio del","year":"2008","unstructured":"del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy. BMC Cancer 8:332\u2013338. doi: 10.1186\/1471-2407-8-332","journal-title":"BMC Cancer"},{"key":"3057_CR10","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. doi: 10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"key":"3057_CR11","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, et al. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205. doi: 10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"3057_CR12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.6004\/jnccn.2007.0019","volume":"5","author":"J Crawford","year":"2007","unstructured":"Crawford J, Althaus B, Armitage J, et al. (2007) Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:188\u2013202","journal-title":"J Natl Compr Canc Netw"},{"key":"3057_CR13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, et al. (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. doi: 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"3057_CR14","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(suppl 5):v248\u2013v251. doi: 10.1093\/annonc\/mdq195","journal-title":"Ann Oncol"},{"key":"3057_CR15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2008.198","volume":"15","author":"CT Kouroukis","year":"2008","unstructured":"Kouroukis CT, Chia S, Verma S, et al. (2008) Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 15:9\u201323","journal-title":"Curr Oncol"},{"key":"3057_CR16","unstructured":"Granix [package insert]. (2013) Teva Pharmaceuticals USA, Inc., North Wales, PA."},{"key":"3057_CR17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/14740338.2013.770472","volume":"12","author":"I Abraham","year":"2013","unstructured":"Abraham I, Tharmarajah S, MacDonald K (2013) Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 12:235\u2013246. doi: 10.1517\/14740338.2013.770472","journal-title":"Expert Opin Drug Saf"},{"key":"3057_CR18","unstructured":"A study to evaluate 5\u00a0\u03bcg\/kg tbo-filgrastim in infants, children and adolescents with solid tumors without bone marrow involvement. NCT02190721. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02190721 . Accessed 2 November 2015."},{"key":"3057_CR19","first-page":"ECR08","volume":"91","author":"NM Nuamah","year":"2006","unstructured":"Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A (2006) Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 91:ECR08","journal-title":"Haematologica"},{"key":"3057_CR20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1537-2995.2003.00384.x","volume":"43","author":"D Stroncek","year":"2003","unstructured":"Stroncek D, Shawker T, Follmann D, Leitman SF (2003) G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 43:609\u2013613","journal-title":"Transfusion"},{"key":"3057_CR21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1757-1626-1-418","volume":"1","author":"N Masood","year":"2008","unstructured":"Masood N, Shaikh AJ, Memon WA, Idress R (2008) Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 1:418. doi: 10.1186\/1757-1626-1-418","journal-title":"Cases J"},{"key":"3057_CR22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ajem.2006.10.005","volume":"25","author":"NJ Watring","year":"2007","unstructured":"Watring NJ, Wagner TW, Stark JJ (2007) Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 25:247\u2013248. doi: 10.1016\/j.ajem.2006.10.005","journal-title":"Am J Emerg Med"},{"key":"3057_CR23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","volume":"40","author":"CC Tigue","year":"2007","unstructured":"Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40:185\u2013192. doi: 10.1038\/sj.bmt.1705722","journal-title":"Bone Marrow Transplant"},{"key":"3057_CR24","unstructured":"Neupogen [package insert]. (2013) Amgen Inc., Thousand Oaks, CA."},{"key":"3057_CR25","unstructured":"EMA-Guideline on good pharmacovigilance practice (GVP). Module VII\u2014periodic safety update report (Rev1) (2015) European Medicines Agency Science Medicines Health. www.ema.europa.eu. Accessed 2 November 2015."},{"key":"3057_CR26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jca.20049","volume":"20","author":"M Martino","year":"2005","unstructured":"Martino M, Console G, Irrera G, et al. (2005) Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 20:129\u2013136. doi: 10.1002\/jca.20049","journal-title":"J Clin Apher"},{"key":"3057_CR27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00277-002-0553-5","volume":"81","author":"DW Beelen","year":"2002","unstructured":"Beelen DW, Ottinger H, Kolbe K, et al. (2002) Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol 81:701\u2013709. doi: 10.1007\/s00277-002-0553-5","journal-title":"Ann Hematol"},{"key":"3057_CR28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1537-2995.1999.39060555.x","volume":"39","author":"P Anderlini","year":"1999","unstructured":"Anderlini P, Donato M, Chan KW, et al. (1999) Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 39:555\u2013560","journal-title":"Transfusion"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3057-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-3057-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-3057-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:09:48Z","timestamp":1559095788000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-3057-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,16]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-3057-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,16]]}}}